目的檢測黑色素瘤抗原基因-3(MAGE-3)在直腸癌中的表達,探索其與直腸癌臨床病理的關(guān)系及其在直腸癌免疫治療中的應(yīng)用價值。
方法采用RT-PCR法,對33例直腸癌患者的癌組織及其相應(yīng)距腫瘤邊緣(5±1) cm的癌旁組織和手術(shù)切緣(乙狀結(jié)腸端)以及3例直腸息肉標本(無瘤)的MAGE-3的表達情況進行檢測,并對RT-PCR擴增產(chǎn)物中的目的基因片段進行DNA測序驗證。
結(jié)果33例直腸癌組織中,MAGE-3基因的表達陽性率為42.42%(14/33),在癌旁組織和手術(shù)切緣組織中,MAGE-3基因的表達陽性率分別為18.18%(6/33)和15.15%(5/33),3例直腸息肉標本未見MAGE-3表達。腫瘤組織MAGE-3基因表達陽性率均顯著高于癌旁組織和手術(shù)切緣組織(P<0.05); 而與患者年齡、性別、腫瘤組織學類型、Dukes分期及淋巴結(jié)轉(zhuǎn)移無關(guān)(P gt;0.05)。
結(jié)論基于MAGE-3基因在直腸癌中的高表達率,MAGE-3表達的蛋白可以作為一種有前途的靶點用于免疫治療,同時有望成為一種篩查和隨訪指標。
引用本文: 李新明,陶凱雄,王國斌,張寧,吳相柏,張景輝,田源. 黑色素瘤抗原基因-3在直腸癌的表達及意義. 中國普外基礎(chǔ)與臨床雜志, 2006, 13(3): 308-310下轉(zhuǎn)320. doi: 復制
版權(quán)信息: ?四川大學華西醫(yī)院華西期刊社《中國普外基礎(chǔ)與臨床雜志》版權(quán)所有,未經(jīng)授權(quán)不得轉(zhuǎn)載、改編
1. | [J]. Int J Cancer, 2003; 104(4)∶ 482. |
2. | [J]. Clin Cancer Res, 2003; 9(7)∶2447. |
3. | |
4. | [J]. Nihon Rinsho Meneki Gakkai Kaishi, 1997; 20(2)∶95. |
5. | [J]. J Korean Med Sci, 2002; 17(4)∶497. |
6. | [J]. Arch Pathol Lab Med, 1998; 122(6)∶551. |
7. | |
8. | [J]. Ann Surg, 1996; 224(2)∶183. |
9. | [J]. Cancer Lett, 2004; 208(2)∶197. |
10. | Eichmuller S, Usener D, Thiel D, et al. Tumorspecific antigens in cutaneous Tcell lymphoma: expression and seroreactivity. |
11. | Ullenhag GJ, Frodin JE, Mosolits S, et al. Immunization of colorectal carcinoma patients with a recombinant canarypox virus expressing the tumor antigen EpCAM/KSA (ALVACKSA) and granulocyte macrophage colonystimulating factor induced a tumorspecific cellular immune response. |
12. | Nishimura S, Fujita M, Terata N, et al. Expression of MAGE genes in colorectal carcinomas. |
13. | Park MS, Park JW, Jeon CH, et al. Expression of melanoma antigenencoding genes (MAGE) by common primers for MAGEA1 toA6 in colorectal carcinomas among Koreans. |
14. | Hasegawa H, Mori M, Haraguchi M, et al. Expression spectrum of melanoma antigenencoding gene family members in colorectal carcinoma. |
15. | Mori M, Inoue H, Mimori K, et al. Expression of MAGE genes in human colorectal carcinoma. |
16. | Gerhardt A, Usener D, Keese M, et al. Tissue expression and seroreactivity of tumorspecific antigens in colorectal cancer. |
- 1. [J]. Int J Cancer, 2003; 104(4)∶ 482.
- 2. [J]. Clin Cancer Res, 2003; 9(7)∶2447.
- 3.
- 4. [J]. Nihon Rinsho Meneki Gakkai Kaishi, 1997; 20(2)∶95.
- 5. [J]. J Korean Med Sci, 2002; 17(4)∶497.
- 6. [J]. Arch Pathol Lab Med, 1998; 122(6)∶551.
- 7.
- 8. [J]. Ann Surg, 1996; 224(2)∶183.
- 9. [J]. Cancer Lett, 2004; 208(2)∶197.
- 10. Eichmuller S, Usener D, Thiel D, et al. Tumorspecific antigens in cutaneous Tcell lymphoma: expression and seroreactivity.
- 11. Ullenhag GJ, Frodin JE, Mosolits S, et al. Immunization of colorectal carcinoma patients with a recombinant canarypox virus expressing the tumor antigen EpCAM/KSA (ALVACKSA) and granulocyte macrophage colonystimulating factor induced a tumorspecific cellular immune response.
- 12. Nishimura S, Fujita M, Terata N, et al. Expression of MAGE genes in colorectal carcinomas.
- 13. Park MS, Park JW, Jeon CH, et al. Expression of melanoma antigenencoding genes (MAGE) by common primers for MAGEA1 toA6 in colorectal carcinomas among Koreans.
- 14. Hasegawa H, Mori M, Haraguchi M, et al. Expression spectrum of melanoma antigenencoding gene family members in colorectal carcinoma.
- 15. Mori M, Inoue H, Mimori K, et al. Expression of MAGE genes in human colorectal carcinoma.
- 16. Gerhardt A, Usener D, Keese M, et al. Tissue expression and seroreactivity of tumorspecific antigens in colorectal cancer.